Back to Agenda
SESSION 10: Making the ME(N)A region a Clinical Trials hub
Session Chair(s)
Angelika Joos, MPHARM
Executive Director, Science & Regulatory Policy, MSD, Belgium
Marco Rafael, PHARMD, MBA, RPH
Regulatory Policy Leader, Roche, Switzerland
Overview This Session will highlight global, regional and local efforts to enhance the Clinical Trials environment. WHO will share how regulatory ecosystem optimisation can be a driver for trial activity, followed by AVAREF exploring cross-country collaboration between regulators and ethics committees. Regulators from Saudi Arabia, Tunisia, Egypt, and the UAE will share national initiatives to strengthen the CTs infrastructure and streamline approvals. The session will close with insights on data quality, patient recruitment, and health literacy in line with ICH and ethical guidelines.
Speaker(s)
Marwa Al Abbas
Senior Clinical Trial Expert, Saudi Food and Drug Authority (SFDA), Saudi Arabia
Rania Ibrahim
General Manager of The General Administration of Clinical Trials, Egyptian Drug Authority (EDA), Egypt
Shaikha Almazrouei
Director of the Reference National Laboratory – Drug Department, Emirates Drug Establishment (EDE), United Arab Emirates
Rhanda Adechina Adehan
Technical Officer - Consultant AVAREF Secretariat, World Health Organization (WHO), Switzerland
Abdul Rouf Palli Valapila, PHD
Director of Operations for Clinical Trial Unit, Hamad Medical Corporation (HMC), Qatar
Mariem Kadri
Pharmacist - Directorate of Pharmacy and Medicine , ANMPS (Agence Nationale Du Médicaments et des Produits de la santé), Tunisia
Have an account?